Loading
A phase 1/2 trial of ABT-101 in non-small-cell lung cancer, run by Anbogen Therapeutics, Inc., now recruiting.
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients is a phase 1/2 interventional study registered as NCT05532696 by Anbogen Therapeutics, Inc., with 61 participants planned, started 2022-09-27 and due to reach its primary completion in 2026-11. Interventions recorded: ABT-101.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HER2-mutant non-small-cell lung cancer, HER2, Non-small-cell lung cancer and the tag pipeline.
Shares HER2-mutant non-small-cell lung cancer, HER2, Non-small-cell lung cancer and the tag pipeline.
Shares Anbogen Therapeutics and the tag pipeline.
Shares HER2, Non-small-cell lung cancer and the tag pipeline.
Shares HER2, Non-small-cell lung cancer and the tag pipeline.
Shares HER2-mutant non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares HER2-mutant non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares HER2-mutant non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/